期刊文献+

FasL表达量与卵巢上皮性癌细胞顺铂敏感性的相关性研究

Correlation between FasL expression and platinum sensitivity in ovary epidermis cancer cells
下载PDF
导出
摘要 目的探讨卵巢上皮性癌患者原发灶癌细胞中FasL表达量与细胞体外对顺铂药物敏感性的相关性。方法收集本院手术切除的85例卵巢上皮性癌细胞组织,采用免疫组化法检测癌组织中的FasL表达量,按照FasL表达量的高低分为阴性组、阳性组以及强阳性组。采用MTT法比较不同组细胞对于顺铂药物的敏感性。结果 85例卵巢癌组织中,FasL表达为强阳性标本11例,占12.9%,阳性标本52例,占61.2%,阴性标本22例,占25.9%。顺铂对FasL表达强阳性的肿瘤组织细胞的IC50值为(15.31±1.17)μmol.L-1,对FasL表达阳性的肿瘤组织细胞的IC50为(23.71±2.36)μmol.L-1,对FasL表达阴性的肿瘤组织细胞的IC50为(28.27±3.31)μmol.L-1,三者比较差异有统计学意义(P<0.05)。结论不同的个体肿瘤组织中FasL表达量有差异,FasL在卵巢上皮性癌细胞中的弱表达是导致卵巢上皮性癌细胞耐药的原因之一。肿瘤化疗过程中及时监测FasL在细胞中的表达水平对于分析药物的疗效以及预测药物耐药现象的发生具有积极的临床意义。 Objective To explore the correlation between FasL expression and platinum sensitivity in ovary epidermis cancer cells.Methods A total of 85 ovary epithelial cancer cell tissues were collected and the expression of FasL was detected.The tissues were divided into 3 groups(a negative group,a positive group,and a strong positive group).MTT method was used to test the platinum sensitivity of the three groups.Results Eleven tissues(12.9%) had negative expression of FasL,52 tissues(61.2%) had positive expression of FasL,and 22 tissues(25.9%) strong positive expression of FasL.The IC50 of the three groups was(15.31±1.17),(23.71±2.36),and(28.27±3.31) μmol·L^-1 respectively.There was statistical difference among the three groups(P〈0.05).Conclusion FasL expression is individually different.Platinum sensitivity is associated with low FasL expression.Monitoring of FasL expression is helpful for the analysis process of drug efficacy and prediction of drug resistance.
出处 《中南药学》 CAS 2010年第6期445-448,共4页 Central South Pharmacy
关键词 FASL 卵巢上皮性癌 顺铂 药物敏感性 FasL ovary exidermis cancer platinum sensitivity
  • 相关文献

参考文献12

  • 1赵霞,钟茜.卵巢癌早期筛查的争议与展望[J].西部医学,2009,21(1):1-2. 被引量:13
  • 2Ozols RF,Bookman MA,Connolly DC,et al.Focus on epithelial ovarian cancer[J].Cancer Cell,2004,5(1):19-24.
  • 3Yang H,Kong W,He L,et al.MicroRNA expression profiling in human ovarian cancer:miR-214 induces cell survival and cisplatin resistance by targeting PTEN[J].Cancer research,2008,68(2):425-433.
  • 4Lee S,Choi EJ,Jin C,et al.Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line[J].Gynecol Oncol,2005,97(1):26-34.
  • 5Gori J,Castano R,Toziano M,et al.Intraperitoneal hyperthermic chemotherapy in ovarian cancer[J].Int J Gynecol Cancer,2005,15(2):233-239.
  • 6Van Haaften-Day C,Russell P,Davies S,et al.Expression of Fas and FasL in human serous ovarian epithelial tumors[J].Hum Pathol,2003,34 (1):74-79.
  • 7Zhang X,Miao X,Sun T,et al.Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer[J].J Med Genet,2005,42(6):479-484.
  • 8Jonson H,Allen P,Peng SL.Inflammatory arthritis requires Foxo3a to prevent Fas ligand-induced neutrophil apoptosis[J].Nat Med,2005,11(6):666-671.
  • 9Abusamra AJ,Zhong Z,Zheng X,et al.Tumor exosomes expressing Fas ligand mediate CD8+T-cell apoptosis[J].Blood Cells Mol Dis,2005,35(2):169-173.
  • 10Earle CC,Schrag D,Neville BA,et al.Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients[J].J Natl Cancer Inst,2006,98(3):172-180.

二级参考文献9

  • 1Ozols,RF,Bookman,MA,Connolly,DC,Daly,MB,Godwin,AK,Schilder,RJ,Xu,X,Hamilton,TC.Focus on epithelial ovarian cancer[].Cancer Cell.2004
  • 2Sjovall K,Nilsson B,Einhorn N.The significance of serum CA 125 elevation in malignant and nonmalignant diseases[].Gynecologic Oncology.2002
  • 3DePriest P D,DeSimone C P.Ultrasound screening for the early detection of ovarian cancer[].Journal of Clinical Oncology.2003
  • 4Fung M F,Bryson P,Johnston M,et al.Screening postmenopausal women for ovarian cancer: a systematic review[].Journal of Obstetrics and Gynaecology.2004
  • 5Piver MS.Hereditary ovarian cancer Lessons from the first twenty years of the Gilda Radner Familial Ovarian Cancer Registry[].Gynecologic Oncology.2002
  • 6HermsenBB,vonMensdorff-PouillyS,BerkhofJ,etal.SerumCA-125inrelation to adnexal dysplasia and cancer in women at hereditaryhighriskofovariancancer[].Clinical Oncology.2007
  • 7Laframboise-S et al.Use of CA-125 and ultrasound in high-risk women[].International Journal of Gynecological Cancer.2002
  • 8Stirling D,Evans DG,Pichert G,et al.Screening for familialovarian cancer:failure of current protocols to detect ovariancancer at an early stage according to the international Federa-tion of gynecology and obstetrics system[].Journal of Clinical Oncology.2005
  • 9Oei,A.L.,Massuger,L.F.,Bulten,J.Surveillance of women at high risk for hereditary ovarian cancer is inefficient[].British Journal of Cancer.2006

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部